The earnings call highlighted significant progress in advancing clinical programs and strong financial performance, especially through strategic partnerships and increased revenue. However, challenges include the discontinuation of CX-904 and a decrease in cash reserves. Overall, the positive aspects slightly outweigh the negatives.

Company Guidance -

Q2 2025

In the fourth quarter of 2024 financial results call, CytomX Therapeutics provided detailed guidance on their pipeline progress and financial outlook. They highlighted the advancement of two new clinical programs, CX-2051 and CX-801, prioritizing these to optimize resource allocation and extending their cash runway to the second quarter of 2026. They aim to generate initial clinical data for both programs in 2025, with CX-2051 targeting colorectal cancer as a first-in-class ADC and CX-801 as a next-generation targeted immunotherapy. Financially, the company reported $138.1 million in revenue for 2024, an increase from $101.2 million in 2023, and ended the year with $100.6 million in cash, cash equivalents, and investments, compared to $174.5 million in 2023. The increase in revenue was attributed to collaborations with companies like Bristol Myers Squibb and Moderna. Total operating expenses for 2024 were $113.1 million, slightly up from $107.7 million in 2023, primarily due to a milestone payment to AbbVie.

Advancement of Clinical Programs

In 2024, CytomX advanced two new programs, CX-2051 and CX-801, into the clinic, prioritizing these programs and streamlining the organization to extend the cash runway to Q2 2026.

Financial Performance

Total revenue for 2024 was $138.1 million, up from $101.2 million in 2023, attributed to collaborations with BMS, Moderna, Astellas, and Regeneron.

Pipeline Progress and Strategic Partnerships

CytomX achieved a $5 million milestone payment from Astellas and continues progress with partnerships involving Bristol Myers Squibb, Amgen, Moderna, and Regeneron.

CytomX Therapeutics (CTMX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CTMX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	-0.06 / -	-0.08	―	―	―
May 12, 2025	2025 (Q1)	0.13 / 0.27	0.17	58.82% (+0.10)
Mar 06, 2025	2024 (Q4)	-0.20 / 0.22	0.02	1000.00% (+0.20)	―
Nov 07, 2024	2024 (Q3)	-0.17 / 0.07	0.04	75.00% (+0.03)	―
Aug 08, 2024	2024 (Q2)	-0.10 / -0.08	-0.02	-300.00% (-0.06)	―
May 08, 2024	2024 (Q1)	-0.10 / 0.17	-0.05	440.00% (+0.22)	―
Mar 11, 2024	2023 (Q4)	-0.05 / 0.02	-0.42	104.76% (+0.44)	―
Nov 07, 2023	2023 (Q3)	-0.19 / 0.04	-0.35	111.43% (+0.39)	―
Aug 08, 2023	2023 (Q2)	-0.19 / -0.02	-0.37	94.59% (+0.35)	―
May 09, 2023	2023 (Q1)	-0.11 / -0.05	-0.37	86.49% (+0.32)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CTMX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 12, 2025	$0.93	$2.13	+129.03%
Mar 06, 2025	$0.62	$0.66	+6.45%
Nov 07, 2024	$1.00	$1.09	+9.00%
Aug 08, 2024	$1.18	$1.20	+1.69%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does CytomX Therapeutics Inc (CTMX) report earnings?

CytomX Therapeutics Inc (CTMX) is schdueled to report earning on Aug 07, 2025, After Close (Confirmed).

What is CytomX Therapeutics Inc (CTMX) earnings time?

CytomX Therapeutics Inc (CTMX) earnings time is at Aug 07, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CTMX EPS forecast?

CTMX EPS forecast for the fiscal quarter 2025 (Q2) is -0.06.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing